Characterization of endoscopic ultrasound fine-needle aspiration cytology by targeted next-generation sequencing and theranostic potential

Ferga C. Gleeson, Benjamin R. Kipp, Sarah E. Kerr, Jesse S. Voss, Konstantinos N Lazaridis, David A Katzka, Michael J. Levy

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Determination of tumor genetic architecture based on tissue analysis yields important information on signaling pathways involved in cancer pathogenesis and plays a growing role in choosing the optimal medical management of malignancies. Specifically, the advent of next-generation sequencing has led to a rapidly evolving era of relatively inexpensive, high-throughput DNA sequencing of tumors. One such example is multiplexed tumor genotyping (ie, panel testing) of more than 2800 mutations across 50 commonly mutated cancer-associated genes. This resulting mutational landscape shows medically actionable pathogenic alterations to optimize antitumor therapy. We recently assessed the performance and outcome of targeted next-generation sequencing with archived endoscopic ultrasound fine-needle aspirates across a broad range of primary and metastatic sites with encouraging accuracy. As a result, endoscopic ultrasound has the potential to move from a test for diagnosis or confirmation of malignancy, to one in which it could facilitate the personalization of cancer-directed therapy.

Original languageEnglish (US)
Pages (from-to)37-41
Number of pages5
JournalClinical Gastroenterology and Hepatology
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Fine Needle Biopsy
Cell Biology
Neoplasms
High-Throughput Nucleotide Sequencing
Neoplasm Genes
Theranostic Nanomedicine
Needles
Mutation
Therapeutics

Keywords

  • Endoscopic ultrasound fine-needle aspiration
  • Individualized medicine
  • Malignant cytology
  • Targeted next-generation sequencing
  • Theranostics

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Characterization of endoscopic ultrasound fine-needle aspiration cytology by targeted next-generation sequencing and theranostic potential. / Gleeson, Ferga C.; Kipp, Benjamin R.; Kerr, Sarah E.; Voss, Jesse S.; Lazaridis, Konstantinos N; Katzka, David A; Levy, Michael J.

In: Clinical Gastroenterology and Hepatology, Vol. 13, No. 1, 01.01.2015, p. 37-41.

Research output: Contribution to journalArticle

@article{d25a965ffc464afdbb7aa5dcb755a178,
title = "Characterization of endoscopic ultrasound fine-needle aspiration cytology by targeted next-generation sequencing and theranostic potential",
abstract = "Determination of tumor genetic architecture based on tissue analysis yields important information on signaling pathways involved in cancer pathogenesis and plays a growing role in choosing the optimal medical management of malignancies. Specifically, the advent of next-generation sequencing has led to a rapidly evolving era of relatively inexpensive, high-throughput DNA sequencing of tumors. One such example is multiplexed tumor genotyping (ie, panel testing) of more than 2800 mutations across 50 commonly mutated cancer-associated genes. This resulting mutational landscape shows medically actionable pathogenic alterations to optimize antitumor therapy. We recently assessed the performance and outcome of targeted next-generation sequencing with archived endoscopic ultrasound fine-needle aspirates across a broad range of primary and metastatic sites with encouraging accuracy. As a result, endoscopic ultrasound has the potential to move from a test for diagnosis or confirmation of malignancy, to one in which it could facilitate the personalization of cancer-directed therapy.",
keywords = "Endoscopic ultrasound fine-needle aspiration, Individualized medicine, Malignant cytology, Targeted next-generation sequencing, Theranostics",
author = "Gleeson, {Ferga C.} and Kipp, {Benjamin R.} and Kerr, {Sarah E.} and Voss, {Jesse S.} and Lazaridis, {Konstantinos N} and Katzka, {David A} and Levy, {Michael J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.cgh.2014.10.017",
language = "English (US)",
volume = "13",
pages = "37--41",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Characterization of endoscopic ultrasound fine-needle aspiration cytology by targeted next-generation sequencing and theranostic potential

AU - Gleeson, Ferga C.

AU - Kipp, Benjamin R.

AU - Kerr, Sarah E.

AU - Voss, Jesse S.

AU - Lazaridis, Konstantinos N

AU - Katzka, David A

AU - Levy, Michael J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Determination of tumor genetic architecture based on tissue analysis yields important information on signaling pathways involved in cancer pathogenesis and plays a growing role in choosing the optimal medical management of malignancies. Specifically, the advent of next-generation sequencing has led to a rapidly evolving era of relatively inexpensive, high-throughput DNA sequencing of tumors. One such example is multiplexed tumor genotyping (ie, panel testing) of more than 2800 mutations across 50 commonly mutated cancer-associated genes. This resulting mutational landscape shows medically actionable pathogenic alterations to optimize antitumor therapy. We recently assessed the performance and outcome of targeted next-generation sequencing with archived endoscopic ultrasound fine-needle aspirates across a broad range of primary and metastatic sites with encouraging accuracy. As a result, endoscopic ultrasound has the potential to move from a test for diagnosis or confirmation of malignancy, to one in which it could facilitate the personalization of cancer-directed therapy.

AB - Determination of tumor genetic architecture based on tissue analysis yields important information on signaling pathways involved in cancer pathogenesis and plays a growing role in choosing the optimal medical management of malignancies. Specifically, the advent of next-generation sequencing has led to a rapidly evolving era of relatively inexpensive, high-throughput DNA sequencing of tumors. One such example is multiplexed tumor genotyping (ie, panel testing) of more than 2800 mutations across 50 commonly mutated cancer-associated genes. This resulting mutational landscape shows medically actionable pathogenic alterations to optimize antitumor therapy. We recently assessed the performance and outcome of targeted next-generation sequencing with archived endoscopic ultrasound fine-needle aspirates across a broad range of primary and metastatic sites with encouraging accuracy. As a result, endoscopic ultrasound has the potential to move from a test for diagnosis or confirmation of malignancy, to one in which it could facilitate the personalization of cancer-directed therapy.

KW - Endoscopic ultrasound fine-needle aspiration

KW - Individualized medicine

KW - Malignant cytology

KW - Targeted next-generation sequencing

KW - Theranostics

UR - http://www.scopus.com/inward/record.url?scp=84916920201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916920201&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2014.10.017

DO - 10.1016/j.cgh.2014.10.017

M3 - Article

C2 - 25424571

AN - SCOPUS:84916920201

VL - 13

SP - 37

EP - 41

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 1

ER -